Evidence map›Paper›PMID 40208233›Full record

ArticleeLife2025

STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer.

Huan Fang, Huichun Liang, Chuanyu Yang, Dewei Jiang, Qianmei Luo, Wen-Ming Cao, Huifeng Zhang, Ceshi Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Deubiquitinases as Regulators and Therapeutic Targets in Vascular Diseases.International journal of molecular sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huan Fang *Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.ORCID https://orcid.org/0009-0003-0489-5796
Huichun Liang *Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.ORCID https://orcid.org/0000-0002-9157-3087
Chuanyu YangKunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Dewei JiangKunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Qianmei LuoKunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
Wen-Ming CaoThe Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Huifeng ZhangDepartment of Pharmacy, the First People's Hospital of Yunnan Province/the Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Ceshi ChenKunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.ORCID https://orcid.org/0000-0001-6398-3516

Funding

Biomedical Projects of Yunnan Key Science and Technology Program 202302AA310046Center of Clinical Pharmacy of the First People's Hospital of Yunnan Province Open Project 2023YJZX-YX04Kunming University of Science and Technology-The First People's Hospital of Yunnan Province Joint Major Project KUST-KH2022005ZNational Key Research and Development Program of China 2023YFA1800500National Key Research and Development Program of China 2023ZD0502200, 2020YFA0112300National Natural Science Foundation of China 82203413National Natural Science Foundation of China U2102203, 82430084The Innovative Research Team of Yunnan Province 202405AS350016Yunnan Fundamental Research Projects 202201AT070290Yunnan Fundamental Research Projects 202301AS070050, 202201BC070002Yunnan (Kunming) Academician Expert Workstation No. Q7 YSZJGZZ-2020025Yunnan Revitalization Talent Support Program Yunling Shcolar
6 · The paper itself

Abstract

In the clinic, anti-tumor angiogenesis is commonly employed for treating recurrent, metastatic, drug-resistant triple-negative, and advanced breast cancer. Our previous research revealed that the deubiquitinase STAMBPL1 enhances the stability of MKP-1, thereby promoting cisplatin resistance in breast cancer. In this study, we discovered that STAMBPL1 could upregulate the expression of the hypoxia-inducible factor HIF1α in breast cancer cells. Therefore, we investigated whether STAMBPL1 promotes tumor angiogenesis. We demonstrated that STAMBPL1 increased

Indexed as

DNA-Binding ProteinsForkhead Box Protein O1Hypoxia-Inducible Factor 1, alpha SubunitNeovascularization, PathologicTranscription FactorsTriple Negative Breast NeoplasmsVascular Endothelial Growth Factor AAngiogenesisAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceSignal TransductionDNA-Binding ProteinsForkhead Box Protein O1FOXO1 protein, humanGRHL3 protein, humanHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitTranscription FactorsVascular Endothelial Growth Factor AVEGFA protein, humancancer biologyFOXO1GRHL3HIF1αhumanSTAMBPL1triple-negative breast cancertumor angiogenesis

Identifiers

PMID40208233
PMCPMC11984952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.